The cost‐effectiveness of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE‐TIMI 58 trial

AIM: To undertake a cost‐effectiveness analysis of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus (T2DM), using both directly observed events in the DECLARE‐TIMI 58 trial and surrogate risk factors to predict endpoints not captured within the trial. METHODS: An establishe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diabetes Obes Metab
Main Authors: McEwan, Phil, Morgan, Angharad R., Boyce, Rebecca, Bergenheim, Klas, Gause‐Nilsson, Ingrid A.M., Bhatt, Deepak L., Leiter, Lawrence A., Johansson, Peter A., Mosenzon, Ofri, Cahn, Avivit, Wilding, John P.H.
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Publishing Ltd 2021
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8048502/
https://ncbi.nlm.nih.gov/pubmed/33368855
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.14308
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados